Treating hepatitis C virus (HCV) infection with direct-acting antiviral (DAA) agents is associated with improved glycemic control in patients with type 2 diabetes, researchers suggest.
- Coffee consumption has been associated with reduced frequency of liver disease.
- Total caffeine intake was not associated with prevalence or hepatic fibrosis of nonalcoholic fatty liver disease.
- Regular coffee caffeine consumption may significantly reduce hepatic fibrosis in patients with nonalcoholic fatty liver disease.
- Coffee consumption can reduce the severity of fibrosis and may contribute to the repair of liver tissue.
- Coffee caffeine is associated with a significant reduction in risk of fibrosis among patients with nonalcoholic steatohepatitis.
- Evidence of risks associated with proton pump inhibitors continues to accumulate.
- Proton pump inhibitors may be overprescribed in place of lifestyle modifications.
- Risk of chronic kidney disease is added to risk of gastrointestinal tract hemorrhage and infectious complications in the intensive care unit potentially attributable to PPI use.
- No causal mechanisms of potential PPI injury have been identified.
- In 2015, 80% of all Medicare spending will be on new, frequently curative treatments of hepatitis C (HCV) infection.
- Medicare spent about $7 million/y on older HCV drugs; will spend about $9 billion on new DAAs in 2015.
- Newer HCV drugs will be accompanied by high cost in the first few years of their use. A precipitous drop in spending is expected once the HCV epidemic is stemmed.
- HCV-related costs will drop sharply in the coming years, to below $2 billion by 2020, and to just $14 million by 2030.
- New DAAs are one of the greatest value propositions in the history of medicine; a fantastic value at a high up-front cost.